When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.
City of Hope researchers presented compelling real-world evidence and novel combination therapies at the 2025 ASCO Annual Meeting, with findings that could reshape treatment approaches for breast, colorectal, renal, and prostate cancers.
The landscape of cancer is shifting beneath our feet, and we must adapt our clinical practice accordingly.
In the rapidly evolving field of oncology, the integration of big data and artificial intelligence is revolutionizing our approach to cancer research and treatment. The future of precision oncology requires integrating computational approaches with clinical practice.
City of Hope researchers at AACR.City of Hope presented more than 74 sessions at this year’s American Association for Cancer Research Annual Meeting in Chicago, highlighting breakthroughs in diagnostics, treatment options and AI-powered precision medicine.
I joined Translational Genomics Research Institute, part of City of Hope, late last year to launch the Center for Accelerated Nanotherapeutics.
The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion.
We are at a transformational period in oncology; the overall mortality from cancer is gradually declining in the United States.
Peritoneal metastases arise from gastrointestinal and gynecologic malignancies, leading to debilitating symptoms and poor prognoses. They remain one of the most challenging manifestations of advanced malignancies, often leading to significant morbidity and limited treatment options.
This year marks the 49th anniversary of the City of Hope bone marrow transplant program, which was conceived and developed by Ernest Beutler and Karl Blume in 1975, with help and inspiration from E. Donnall Thomas, the 1990 Nobel Laureate in Physiology and Medicine.
